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Antiangiogenic therapy typically results in
transient tumor response. Rivera et al.
show that therapy induces antitumor
behavior in myeloid cells, which
subsequently become tumor promoting
via PI3K activation. Targeting distinct
myeloid populations results in increases
in nontargeted myeloid cells, creating an
oscillating pattern of resistance. Myeloid-
cell PI3K inhibition overcomes such
resistance and enhances therapeutic
efficacy.
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Antiangiogenic therapy is commonly used in the
clinic, but its beneficial effects are short-lived, lead-
ing to tumor relapse within months. Here, we found
that the efficacy of angiogenic inhibitors targeting
the VEGF/VEGFR pathway was dependent on in-
duction of the angiostatic and immune-stimulatory
chemokine CXCL14 in mouse models of pancreatic
neuroendocrine and mammary tumors. In response,
tumors reinitiated angiogenesis and immune sup-
pression by activating PI3K signaling in all CD11b+
cells, rendering tumors nonresponsive to VEGF/
VEGFR inhibition. Adaptive resistance was also
associated with an increase in Gr1+CD11b+ cells,
but targeting Gr1+ cells was not sufficient to further
sensitize angiogenic blockade because tumor-asso-
ciated macrophages (TAMs) would compensate for
the lack of such cells and vice versa, leading to an
oscillating pattern of distinct immune-cell popula-
tions. However, PI3K inhibition in CD11b+ myeloid
cells generated an enduring angiostatic and im-
mune-stimulatory environment in which antiangio-
genic therapy remained efficient.
INTRODUCTION
Antiangiogenic therapy represents one of the most widely used
anticancer strategies today, with most approved therapies tar-
geting the vascular endothelial growth factor (VEGF) signaling
pathway. However, since the beneficial effects observed across
the multitude of cancers that respond to such treatment are typi-
cally short-lived, much effort has focused on uncovering the
various mechanisms whereby tumors bypass the tumor-inhibi-
tory effects of therapy (Bergers and Hanahan, 2008; Kerbel,
2008). One such resistance mechanism involves reinstatementof angiogenesis by tumor-infiltrating innate immune cells
(De Palma et al., 2005; Fischer et al., 2007; Shojaei et al.,
2007a, 2007b).
Tumors can contain a significant percentage of different infil-
trating myeloid cells with bivalent functions, but predominantly
are thought to support tumor progression by promoting angio-
genesis and suppressing antitumor immunity. Tumor-associated
macrophages (TAMs) are typically characterized as either ‘‘clas-
sically’’ activated tumoricidal macrophages (M1) or ‘‘alterna-
tively’’ activated protumorigenic macrophages (M2) (Mantovani
et al., 2008). Extending this nomenclature, tumor-associated
neutrophils (TANs) have also been categorized as N1 or N2
based on their anti- or protumor activity in tumors (Fridlender
et al., 2009). In addition, immature Gr1+ cells with either a mono-
nuclear or granular morphology have been identified in tumors
that convey immune-suppressive functions, and thus are also
termed myeloid-derived suppressor cells (M-MDSC and G-
MDSC, respectively) (Talmadge and Gabrilovich, 2013). Typi-
cally, surface-marker profiling based on expression of CD11b,
F4/80, Gr1, Ly6C, and Ly6G is used to categorize these subsets
of tumor-infiltrating myeloid cells (Fridlender et al., 2009; Tal-
madge and Gabrilovich, 2013; Wynn et al., 2013).
There is mounting evidence that tumors recruit these distinct
populations, which then become an additional source of angio-
genic chemokines and cytokines to promote angiogenesis
(Coussens et al., 2000; Du et al., 2008; Giraudo et al., 2004;
Lin et al., 2006; Shojaei et al., 2007b). Given that hypoxia is a
major driver of myeloid-cell recruitment (Du et al., 2008; Maz-
zieri et al., 2011), it is conceivable that therapy-induced hypoxia
via an angiogenic blockade can induce factors that mobilize
cells from the bone marrow and attract them to the tumor
site. Indeed, tumor-associated myeloid cells have been shown
to sustain angiogenesis in the face of antiangiogenic therapy, in
part by stimulating VEGF-independent pathways. For example,
macrophages were shown to induce the expression of various
angiogenic molecules, including FGF-1,2, MMP9, and Ang2, in
response to antiangiogenic therapy (Casanovas et al., 2005;
Fischer et al., 2007; Rigamonti et al., 2014), and Gr1+ myeloidCell Reports 11, 577–591, April 28, 2015 ª2015 The Authors 577
cells were found to convey resistance to anti-VEGF treatment
via secretion of the angiogenic PKR-1/2 ligand Bv8 (Shojaei
et al., 2007a, 2007b). Even though inhibitors of macrophages
or Gr1+ cells enhanced the effects of antiangiogenic therapy,
in many of these models tumor growth still occurred, albeit at
a slower pace, throughout the duration of treatment. Here,
we investigated the overall contributions of different tumor-
associated myeloid populations to evasion of antiangiogenic
therapy. We analyzed the composition and function of TAMs,
TANs, and two Gr1+ immature monocyte populations in two
distinct tumor models that responded differently to angiogenic
inhibition. In the Rip1Tag2 model of pancreatic neuroendocrine
tumor (PNET), angiogenic blockade was able to transiently
reduce vessel density and block tumor growth (response) fol-
lowed by reinstatement of neovascularization and robust tumor
growth (relapse), which enabled us to evaluate true ‘‘response’’
and ‘‘relapse’’ phases in a single model. In the PyMT mammary
carcinoma model, angiogenic blockade was only able to slow
down tumor growth, with some reduction in vessel density, a
feature that is commonly observed in various tumor models.
Analysis of myeloid-cell content within tumors revealed that
the angiogenic relapse was associated with an increase in tu-
mor-specific subsets of Gr1+ myeloid cells. By investigating
the role of these cells during relapse, we were able to uncover
a compensatory nature of myeloid-cell-mediated resistance to
antiangiogenic therapy. We sought to determine the mecha-
nisms by which distinct innate immune cells compensate for
each other to maintain resistance, and to identify ways to
modulate inflammation so as to sustain the effects of antiangio-
genic therapy.
RESULTS
Targeting Distinct Myeloid Subtypes Leads to a
Compensatory Oscillation between Innate Immune
Cells, Enabling Reneovascularization during
Antiangiogenic Therapy
We established a model of evasive resistance to antiangiogenic
therapy in the Rip1Tag2 (RT2) model of PNET. Treatment of
13-week-old tumor-bearing mice with the broad-spectrum an-
giokinase inhibitor sorafenib induced a 2- to 3-week period of
response characterized by tumor stasis followed by robust tu-
mor growth and subsequent death (Figure 1A). The onset of
sorafenib response and relapse is similar to that observed
with DC101, a VEGFR2-neutralizing antibody, supporting the
notion that sorafenib predominantly blocks the VEGF/VEGFR2
pathway in PNET (Casanovas et al., 2005; Rigamonti et al.,
2014; G.B., unpublished data). Tumor analysis during the
response phase (2-week treatment, 15 weeks of age) with sor-
afenib revealed a substantial reduction in vessel density and
hemorrhage formation, whereas relapsing tumors (4-week treat-
ment, 17 weeks of age) exhibited a vascular pattern similar to
that of untreated tumors, with high vessel density and hemor-
rhage recurrence (Figure 1B). Thus, we defined ‘‘responding’’
tumors as those treated from 13 to 15 weeks of age (2 weeks),
and ‘‘relapse’’ tumors as those treated from 13 to 17 weeks of
age (4 weeks). Therefore, RT2-PNETs overcome vascular
growth restrictions by gaining the capability to reinitiate neovas-578 Cell Reports 11, 577–591, April 28, 2015 ª2015 The Authorscularization. When we investigated the intratumoral composition
of innate immune cells, fluorescence-activated cell sorting
(FACS) analysis of PNETs during the course of treatment re-
vealed no substantial difference in the number or composition
of myeloid cells during the response phase (Figures 1C, S1A,
S1B, and S2A). However, a substantial increase in intratumoral
Gr1+Ly6CHi monocytes (SSCLowCD11b+Gr1LowLy6CHighLy6-
GLow) accompanied the angiogenic relapse (Figures 1C, S1A,
and S2A). As elevated levels of infiltrating Gr1+ myeloid cells
were previously found to promote tumor resistance to anti-
VEGF therapy (Shojaei et al., 2007a), we targeted relapse-asso-
ciated Gr1+ cells 2 weeks after the start of antiangiogenic
therapy, when the tumors were still responding to sorafenib
(Figure 1D). Although it blocked the increased accumulation of
Gr1+ cells within the tumor (Figures 1F, S1A, S1B, and S2B),
this approach did not prolong responsiveness to sorafenib
and led to a proangiogenic relapse similar to that observed
with sorafenib alone (Figure 1E). Furthermore, reducing Gr1+
cell infiltration induced a compensatory increase in TAMs to
potentially confer therapeutic resistance (Figures 1F, S1A,
S1B, and S2B). Hence, we investigated whether TAM depletion
with a CSF1-neutralizing antibody would be more beneficial for
sustaining a sorafenib response. However, this approach was
also unable to prolong the response to antiangiogenic therapy
(Figures 1G and 1H), as it induced an increase in intratumoral
Gr1+Ly6GHi and Gr1+Ly6CHi monocytes and TAN (Figures 1I,
S1A, and S2C). Thus, Gr1+ cells compensate for TAM depletion
and vice versa—a phenomenon that is reminiscent of an oscil-
lating pattern of innate immune cells to convey therapeutic
resistance to antiangiogenic therapy. These results imply that
several myeloid-cell populations regulate reneovascularization
and promote it in a compensatory manner.
Upregulation of Angiostatic Chemokines Is Associated
with the Antiangiogenic Effects of Sorafenib in PNET
To elucidate how myeloid-cell oscillation promotes a proangio-
genic relapse during sorafenib therapy, we compared the gene
expression of several prominent angiogenic factors among
naive, responding, and relapsing PNETs of RT2 mice treated
with sorafenib alone or in combination with either anti-Gr1 or
anti-CSF1. Interestingly, compared with naive tumors, res-
ponse-phase tumors displayed enhanced levels of several
prominent proangiogenic factors despite exhibiting substantial
vessel reduction (Figures 2A, S3A, and S3B). They remained at
similar levels in the relapse phase regardless of whether the
mice received sorafenib alone or in combination with anti-Gr1
or anti-CSF1 treatment (Figures 2A, S3A, and S3B). In contrast,
expression analysis of various angiostatic chemokines in tumors
showed thatCXCL14was dominantly upregulated in responding
tumors, followed to a lesser extent by CXCL4 (Figures 2A, S3C,
and S3D). Both chemokines returned to base level upon tumor
relapse with sorafenib alone or in combination with anti-Gr1 or
anti-CSF1 treatment. Expression of the angiogenic factor BV8
and antiangiogenic molecules thrombospondin-1 and thrombo-
spondin-2 did not change throughout the duration of treatment
(data not shown). These results suggest that in PNETs, the
angiogenic response and relapse during sorafenib treatment is
not determined by upregulation of proangiogenic factors, but
Figure 1. Targeting Distinct Myeloid Populations Induces Compensatory Oscillation
(A) Tumor burden of RT2mice. Response indicates tumor stasis (2-week sorafenib treatment) and relapse indicates tumor regrowth (4-week sorafenib treatment).
(B) Microvessel density of immunofluorescent anti-CD31-stained tumors.
(C) Myeloid cell composition in RT2 PNET by FACS. p = 0.0248 for relapse- versus response-phase Gr1+Ly6CHi cells.
(D–F) Tumor burden (D), microvessel density (E), and myeloid cell composition (F) in mice treated with sorafenib plus anti-Gr1. p = 0.01 for TAM versus sorafenib
response-phase TAM; p = 0.007 for Gr1+Ly6CHi cells and TAM versus cognate populations in sorafenib relapse tumors.
(G–I) Tumor burden (G), microvessel density (H), andmyeloid cell composition (I) in mice treatedwith sorafenib plus anti-CSF1. p < 0.05 for TAM, Gr1+Ly6CHi, and
Gr1+Ly6GHi cells versus cognate populations in both sorafenib response- and relapse-phase tumors. Scale bars, 100 mm. Mean ± SEM is presented for all
quantitation.
In (D)–(I), data are presented with untreated and sorafenib response tumor data from (A)–(C). See also Figures S1 and S2 and Experimental Proceduresfor details.rather by the levels of angiostatic chemokines, specifically
CXCL14.
Myeloid Cells Regulate Angiogenic Response and
Relapse in PNET
We then sought to determine the extent to which intratumoral
myeloid cells are the source of intratumoral angiogenic factors.
We isolated TAMs, Gr1+Ly6CHi, and Gr1+Ly6GHi monocytes,
and TAN from RT2 PNET of untreated mice and mice treated
for 2 or 4 weeks with sorafenib (alone or in combination with
anti-Gr1 or anti-CSF1), and compared their angiogenic gene
expression profiles with that of the entire tumor (Figures 2A–
2E). Surprisingly, proangiogenic and angiostatic factor gene
expression was very similar among all four myeloid populations
and reflected that found in whole-tumor extracts. Furthermore,
proangiogenic factor gene expression was increased in all
four myeloid cell types isolated from responding tumors, andremained unchanged when the tumors became refractory. In
contrast, angiostatic CXCL chemokine expression was low in
myeloid cells of untreated and relapsing tumors, but was upre-
gulated in cells from responding tumors, with CXCL14 being
the most upregulated factor, followed by CXCL4 (Figures 2A–
2E). Given that expression of all CXCL chemokines was unde-
tectable in CD45+ cell-depleted tumor samples, innate immune
cells appear to be the primary source of these chemokines (data
not shown). These results have several implications. First, as the
angiogenic expression profile of all tumor-associated innate im-
mune cells reflects that of the whole tumor, myeloid cells appear
to be the dominant regulators of the angiostatic and proangio-
genic status of PNET during antiangiogenic therapy. Second,
each myeloid population expressed similar angiogenic factors
at comparable levels, arguing that they compensate for each
other by redundant expression of these genes. Third, all four
innate immune-cell types induced antiangiogenic activities inCell Reports 11, 577–591, April 28, 2015 ª2015 The Authors 579
Figure 2. Antiangiogenic Therapy Regulates Both Angiogenic and Angiostatic Gene Expression in Myeloid Cells
(A) qPCR-based expression analyses of proangiogenic and angiostatic genes in RT2 tumors.
(B–E) qPCR expression analysis of FACS-sorted TAMs (B), Gr1+Ly6CHi monocytes (C), Gr1+Ly6GHi monocytes (D), and TANs (E) isolated from tumors treated as
indicated. Dotted lines indicate baseline gene expression in untreated samples.
Mean ± SEM is presented for quantitation; p values were calculated comparing each treatment group with the untreated (UT) group. See also Figure S3.responding tumors concomitantly with CXCL14 upregulation,
and became proangiogenic in relapsing tumors when they lost
their ability to enhance CXCL14 expression.
CXCL14 Thwarts the Angiogenic Activity of Intratumoral
Myeloid Cells
Next, we investigated whether blocking CXCL14 would be suffi-
cient to abrogate the antiangiogenic effects of sorafenib in PNET.
For this purpose, we used aortic slices cultured ex vivo in the580 Cell Reports 11, 577–591, April 28, 2015 ª2015 The Authorspresence of protein extracts made from CD11b+ cells isolated
from untreated, 2-week sorafenib-treated (response phase) or
4-week sorafenib-treated (relapse phase) tumors (Figure 3A).
Only CD11b+ cells from refractory tumors induced endothelial
cell outgrowth and migration from aortic slices (Figure 3A). The
addition of a CXCL14-neutralizing antibody rendered CD11b ex-
tracts from responding tumors angiogenic, but had no impact on
the activities of CD11b extracts from untreated or refractory tu-
mors (Figure 3A). Furthermore, recombinant CXCL14 blocked
Figure 3. Myeloid CXCL14 Induction Is Necessary for Sorafenib to Elicit an Antiangiogenic Response
(A) Aortic slice assay using CD11b+ cell extracts from untreated and treated RT2 tumors as indicated. Endothelial cell migration from the aortic slice
into the surrounding collagenmatrix was assessed by immunofluorescent staining of CD31. Quantitation of migrating cells per slice is presented in the right panel.
*p < 0.01.
(B) Tumor burden of RT2 mice treated with either anti-CXCL14 or control IgG antibody plus sorafenib.
(C) CD31 staining and quantitation of microvessel density of RT2 tumors. Data from untreated mice and mice treated with sorafenib for 4 weeks from Figures 1A
and 1B are presented in (B) and (C) for comparison. Mean ± SEM is presented for all quantitation.the activity of CD11b extracts from refractory tumors (Figure 3A).
These results argue thatCXCL14 levels determine the angiogenic
activity of myeloid cells in PNETs.We then treated RT2mice with
sorafenib in the presence of a neutralizing anti-CXCL14 antibody
or control immunoglobulin G (IgG) beginning at 13 weeks of age.
Mice that received the control combination exhibited a typical
therapeutic response characterized by reduced tumor burden
at 15 weeks and a reduction in microvessel density (Figures 3B
and 3C). Neutralization of CXCL14, however, abrogated the ther-
apeutic effects of sorafenib, because both tumor burden andmi-
crovessel density were comparable to those of untreated mice
(Figures 3B and 3C). Thus, myeloid-cell-produced CXCL14 is
necessary to induce an antiangiogenic response and must be
suppressed to enable a proangiogenic tumor relapse during anti-
angiogenic therapy.Antiangiogenic Therapy Promotes an Immune-
Stimulating Phenotype in Myeloid Cells during
Response that Becomes Immune Suppressive
Concomitantly with Tumor Relapse
CXCL14 is not only an angiostatic factor but has also been
described to induce dendritic cell maturation, thus stimulating
an immune response (Schaerli et al., 2005). As angiogenesis
has been found to correlate with immune suppression in different
tumors (Motz and Coukos, 2011), we hypothesized that antian-
giogenic therapy would change the immune status of tumor-
associated myeloid cells, thereby inducing angiostatic activities
in these populations. In support of this hypothesis, we found
that tumors responding to antiangiogenic therapy exhibited an
induction of proinflammatory gene expression and a reduction
in immunosuppressive gene expression. In refractory tumors,Cell Reports 11, 577–591, April 28, 2015 ª2015 The Authors 581
(legend on next page)
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proinflammatory gene expression levels went to baseline,
whereas the expression of immunosuppressive genes was
enhanced (Figures 4A, S4E, and S4F).
To confirm that the changes in inflammatory gene expression
in whole tumors were a reflection of those in innate immune cells,
we examined the immune expression profile of the four myeloid
cell populations isolated from responding and relapsing tumors.
Surprisingly, not only TAM and TAN but also both Gr1+ mono-
cyte populations displayed an immune-stimulating phenotype
in responding tumors that reverted upon tumor relapse (Figures
4B–4E). TAM exhibited increased expression of the proinflam-
matory cytokines IL-12 and IL-23 and the proinflammatory
response gene TNFa in responding tumors, which remained
elevated, albeit at a lower level, in relapsing tumors. This was
counteracted by upregulation of the immunosuppressive factors
MMR,CCL22, andArg1 in relapsing tumors (Figure 4B). Similarly
to TAM, all Gr1+ populations showed increased expression of
proinflammatory genes (TNFa, CCL11, IL-12, and IL-23) in re-
sponding tumors, which became reduced to or below baseline
levels in relapsing tumors. In contrast, expression of immuno-
suppressive factors, including IL-10 and Arg1, was reduced in
all Gr1+ populations from responding tumors and returned to
baseline levels upon tumor relapse (Figures 4C–4E).
To validate that the different myeloid cells were immune stim-
ulating in responding tumors and immune suppressive in relaps-
ing tumors, we analyzed T cell numbers and activity. Infiltrating
CD8+ cytotoxic T cells (CTLs) increased in tumors responding
to therapy and then dropped to levels observed in untreated tu-
mors as the tumors relapsed (Figure 4F). Concomitantly, CD8+
cells isolated from responding tumors, but not from untreated
or relapsing tumors, expressed elevated Perforin mRNA and
Granzyme B protein levels, indicative of activation (Figures 4G
and S4A). CD4+ T cells did not change in number during sorafe-
nib treatment, but exhibited lower IL-10 expression during
response, suggesting a reduction in CD4+ regulatory T cells (Fig-
ures S4B and S4C).
Next, to test whether the changes in myeloid cell phenotype
were responsible for the different T cell behaviors in responding
and relapsing tumors, we assessed the ability of myeloid cells to
stimulate CD8+ T cell proliferation. Using a coculture assay in
which myeloid cells from RT2 spleens were mixed with naive
CD8+ T cells, we found that macrophages and Gr1+ monocytes
isolated from untreated and relapse-phase RT2 tumors sup-
pressed CD8+ T cell proliferation, whereas response-phase
myeloid cells permitted CD8+ T cell proliferation (Figure 4H).
We obtained similar results with CD11b+ cells isolated from
untreated, responding, or refractory tumors (Figure S4D). TheseFigure 4. Antiangiogenic Therapy Induces Myeloid Cell Polarization
(A–E) qPCR RNA analyses of immune-modulating genes fromRT2 tumors (A), RT2
TANs (E) untreated or treated as indicated; p values were calculated by compari
(F) FACS-analysis of intratumoral CD8+ CTLs.
(G) qPCR analysis of Perforin in CD8+ CTLs.
(H) CFSE-based proliferation assay of CD8+ T cells cocultured with splenic mye
(I–K) Tumor burden (I), apoptosis (J), and microvessel density (K) in mice tre
and sorafenib relapse data from Figures 1A and 1B.Mean ±SEM is presented for a
(4-week sorafenib); mito, Mitomycin C.
See also Figure S4 and Supplemental Experimental Procedures for details.results suggest that CTLs contribute to the therapeutic effects of
antiangiogenic therapy. Indeed, CD8+ T cell depletion in RT2
mice resulted in a lower response to sorafenib, as tumor burden
was increased and tumor cell apoptosis decreased compared
with tumors treated with sorafenib plus IgG control, albeit at sta-
tistically nonsignificant levels (Figures 4I and 4J). This intermedi-
ate response stemmed from sorafenib’s ability to reduce overall
vessel density and induce apoptosis in the absence of CTL cells,
due to CXCL14 upregulation (Figure 4K).
These results demonstrate that antiangiogenic therapy drives
the polarization of TAM, TAN, and both Gr1+ monocytes to an
immune-stimulating type, promoting CTL proliferation and
activation that coincides with their angiostatic activity, leading
to vessel reduction, enhanced tumor cell apoptosis, and subse-
quent tumor growth blockade. However, this effect is transient,
as all four myeloid cell populations become skewed toward
an immunosuppressive phenotype in refractory PNETs, lead-
ing to immune suppression, reneovascularization, and tumor
regrowth.
Activation of PI3K Signaling in Myeloid Cells Promotes
Immune Suppression and Reneovascularization during
Antiangiogenic Therapy
Our results revealed that myeloid cells in untreated tumors
differed from those in relapsing tumors undergoing sorafenib
treatment. Themyeloid cells were not only increased in relapsing
tumors but also displayed elevated levels of immune-suppres-
sive and proangiogenic factors, and lower levels of immune-
stimulating molecules compared with myeloid cells in untreated
tumors. Thus, we hypothesized that PNETs activate myeloid
cells to further promote inflammation and subsequent tumor
relapse. Indeed, we identified enhanced levels of tumor-derived
growth factors and chemokines, including SDF1a and IL-6 (Fig-
ures S5A–S5C) in relapsing tumors. Both SDF1a and IL-6 were
previously shown to mediate myeloid infiltration and subsequent
tumor progression through activation of PI3Kg in myeloid cells
(Schmid et al., 2011). Congruent with the finding that both g
and d isoforms of PI3K are immune-cell specific, we found that
TAM, TAN, and GR1+ monocytes expressed both isoforms,
whereas PNET cells did not (Figure S5D; Hirsch et al., 2000;
Rommel et al., 2007). To determine PI3K activation in intratu-
moral myeloid cells, we assessed the phosphorylation of ribo-
somal protein S6, a downstream target of PI3K, in CD11b+ cells
of untreated and sorafenib-responding and relapsing PNETs
(Figures 5A and 5B). While only about 18%–20% of tumor-asso-
ciated CD11b+ cells exhibited PI3K activity in untreated or re-
sponding tumors, up to 80% of myeloid cells were activated intumor-isolated TAMs (B), Gr1+Ly6CHi (C) and Gr1+Ly6GHi monocytes (D), and
ng total untreated gene expression.
loid populations from RT2 mice treated as indicated.
ated concurrently with sorafenib plus anti-CD8a compared with untreated
ll quantitations. UT, untreated; Resp, response (2-week sorafenib); Rel, relapse
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Figure 5. The PI3Kg/d Inhibitor IPI145 Enhances the Efficacy of Antiangiogenic Therapy
(A) Key downstream effectors of the PI3K signaling pathway.
(B) pS6 and CD11b immunofluorescent staining in RT2 PNET. Quantitation of CD11b+ pS6+ cells is shown on the right; **p < 0.005 versus sorafenib 2 weeks;
###p < 0.0005 versus sorafenib 4 weeks alone and plus antibodies.
(C) CD45 and pS6 staining and quantitation in PNET samples from patients treated as indicated. Each dot represents one patient. Scale bars, 7.5 mm.
(D and E) Tumormicrovessel density (D) and burden (E) frommice treated with sorafenib plus IPI145 versus untreated and sorafenib response-phase tumors from
Figures 1A and 1B.
(F) Survival of RT2 mice treated with vehicle (n = 4; median survival = 102 days), sorafenib (n = 4; median survival = 118.5 days), sorafenib plus IPI145 (n = 10;
median survival = 144 days), or IPI145 alone (n = 4;median survival = 102 days). ns, no significance versus vehicle. *p = 0.0266 versus vehicle; #p = 0.00068 versus
sorafenib. Vertical dashed line indicates the start of sorafenib treatment (91 days); red dotted line indicates 50% survival.
(G) Myeloid cell composition of tumors treated with sorafenib plus IPI145 compared with untreated and sorafenib-treated tumors from Figure 1C. p% 0.05 for
Gr1+Ly6CHi monocytes and TAM from 4-week sorafenib alone versus 4-week sorafenib plus IPI145.
(H and I) qPCR analyses of immune- (H) or angiogenesis- (I) modulating genes from RT2 tumors. PNETs treated with sorafenib plus IPI145 are compared with
untreated and sorafenib-treated tumors from Figure 3A; p valueswere calculated by comparing each treatment with untreated (UT) samples. Dotted lines indicate
baseline gene expression in untreated samples. Mean ± SEM is presented for all quantitations.
See also Figure S5.
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relapsing tumors (Figure 5B). Importantly, analysis of human
PNET biopsies from naive patients or patients who had been
treated with the chemotherapeutic agent 5-FU or bevacizumab
until relapse revealed that only patients who had received beva-
cizumab displayed an increase of activated intratumoral myeloid
cells, as visualized by phosphorylated S6 (pS6) staining in
CD45+ immune cells, confirming the results in the RT2 PNET
model (Figure 5C). These data suggest that PNETs become re-
fractory to antiangiogenic therapy by activating PI3K signaling
in myeloid cells.
Inhibiting PI3K in Myeloid Cells Enhances the Efficacy
and Endurance of Antiangiogenic Therapy
If induced PI3K signaling mediates an immunosuppressive and
proangiogenic switch in myeloid cells that blocks the tumor-
inhibitory effects of sorafenib, then inhibition of PI3K activity
should suffice to prolong the tumor response. To test this prop-
osition, we pharmacologically blocked PI3K in myeloid cells us-
ing the small-molecule inhibitor IPI145, which targets both PI3Kg
and PI3Kd, and is currently being tested in several clinical trials
(e.g., NCT02004522, NCT02049515, and NCT02204982) for he-
matological malignancies. We first confirmed that IPI145 selec-
tively inhibited myeloid cell proliferation and PI3K-mediated
Akt phosphorylation in vitro (Figures S5E and S5F). We then
started sorafenib treatment of RT2 mice at 13 weeks of age
and added IPI145 to the treatment modality at 15 weeks of
age, when the RT2 mice were still responding to sorafenib. After
2 weeks of combined myeloid PI3K inhibition and sorafenib
treatment, we confirmed that IPI145 blocked PI3K activity in
CD11b+ myeloid cells (Figure 5B). Consequently, IPI145 treat-
mentmaintained the lowmicrovessel density observed in tumors
responding to sorafenib (Figure 5D) and impaired tumor re-
growth (Figure 5E), which nearly doubled the overall survival of
the RT2 mice (Figure 5F). Notably, congruent with our observa-
tion that myeloid-PI3K activity was low in untreated RT2 PNETs,
IPI145 alone had no effect on the survival of the RT2 mice (Fig-
ures 5B and 5F). This underscores the notion that in PNETs,
PI3K activity is switched on in myeloid cells as a distinct step
during therapeutic resistance.
To understand how inhibition of PI3K signaling in myeloid cells
enables a sustained response to antiangiogenic therapy, we as-
sessed the composition and status of the tumor-associated
myeloid cell populations. Myeloid cells from tumors of RT2
mice treated with sorafenib plus IPI145 revealed a reduction
in intratumoral Gr1+Ly6CHi monocytes and TAM (Figures 5G
andS5G). Importantly, IPI145 inhibited both the repression of im-
mune-stimulating gene expression and the induction of immune-
suppressing gene expression observed in tumors undergoing
relapse during antiangiogenic therapy (Figure 5H). Furthermore,
IPI145 reduced the expression of proangiogenic factors and
maintained high levels of CXCL14 and CXCL4 (Figure 5I). The
changes in gene expression profiles directly reflected the effects
of IPI145 on myeloid cells because the proinflammatory and an-
giostatic expression patterns of whole tumors reflected those of
TAM, Gr1+Ly6CHi and Gr1+Ly6GHi monocytes, and TAN (Fig-
ures 6A–6D). Moreover, the immune-stimulating nature of these
cells was confirmed by an increase in tumor-associated CTLs
and their expression of Perforin (Figures 6E and 6F). Altogether,these results confirm that myeloid cells undergo a PI3K-medi-
ated switch to become immune suppressive and proangiogenic,
and thus facilitate tumor relapse during antiangiogenic therapy.
They also demonstrate that simultaneous inhibition of PI3K
signaling in all myeloid cell subtypes overcomes the oscillating
resistance observed when distinct myeloid cell subpopulations
are targeted.
PI3K-Activated Myeloid Cells in PyMT Tumors Limit the
Efficacy of Antiangiogenic Therapy
As PNETs contain a majority of inert CD11b+ cells in which PI3K
is inactive, but induce myeloid-PI3K signaling to curtail angio-
genesis inhibition, we hypothesized that the number of PI3K-
activated myeloid cells could determine the effects of antiangio-
genic agents in cancers. To test this proposition, we required a
model in which anti-VEGF therapy would be only partially effec-
tive. We employed an orthotopic mouse model of breast cancer
driven by the MMTV-PyMT transgene, a system that is widely
used to study the impact of myeloid cells during tumor progres-
sion, together with the anti-VEGFR2 antibody DC101 (DeNardo
et al., 2009; Coussens et al., 2013; Mazzieri et al., 2011; Lin
et al., 2003). In contrast to the PNET model, antiangiogenic ther-
apy did not produce distinct response or relapse phases in PyMT
tumors, but slowed down the pace of growth by 33% (Figure 7A).
Analysis of tumors after a 12-day treatment revealed that DC101
reduced microvessel density by 37%, whereas TAN and Gr1+
monocytes increased, leading to a modest elevation of myeloid
cells (Figures 7B, 7C, and S7B). Interestingly, as in the RT2
PNETs, anti-Gr1 reduced the number of TAN and Gr1+Ly6GHi
monocytes while increasing intratumoral TAM. Conversely,
anti-CSF1 reduced the number of TAM and increased TAN con-
tent, displaying again an oscillating pattern of resistance (Figures
7C and S7B). Thus, combinatorial treatment of DC101with either
anti-Gr1 or anti-CSF1 did not reduce tumor growth or vessel
density compared with DC101 alone, and neither antibody alone
affected tumor growth (Figures 7B and S7A).
Then, we investigated whether the PI3K-activation status in
tumor-associated myeloid cells was responsible for the partial
response to antiangiogenic therapy. Indeed, analysis of pS6 ki-
nase+CD11b+cells in untreated tumors revealedPI3Kactivation
in 46.2% of tumor-associated myeloid cells (Figure 7D), a >2.5-
fold higher percentage than what we observed in naive RT2 tu-
mors (Figure 5B). Therefore, IPI145 alone elicited an intermediate
response. DC101 treatment also produced an intermediate
response, but nearly doubled the population of PI3K-activated
myeloid cells (Figure 7D). Congruently, we found that DC101
induced expression of the immunosuppressive genes IL-10 and
TGFb1 as early as 4 days after the start of therapy, without
affecting expression of the proinflammatory genes IL-23 and
TNFa (Figure 7H). Further, as in the PNETmodel, DC101 induced
expressionof theproangiogenic genesVEGFandbFGFconcom-
itantly with an increase in expression of bothCXCL14 andCXCL4
(Figure 7I). These data suggest that the immune-suppressive
and proangiogenic activities of PI3K-activated myeloid cells
outweigh the immune-stimulatory and angiostatic activities of
the PI3K-nonactive myeloid cells, thus explaining the intermedi-
ate response to antiangiogenic therapy (Figures 7H and 7I).
Therefore, blocking PI3K in myeloid cells should be sufficient toCell Reports 11, 577–591, April 28, 2015 ª2015 The Authors 585
Figure 6. IPI145 Induces Immune Stimulatory and Angiostatic Factors in Myeloid Cells during Antiangiogenic Therapy
(A–D) qPCR analyses of TAMs (A), Gr1+Ly6CHi (B) and Gr1+Ly6GHi monocytes (C), and TANs (D) from tumors of RT2 mice treated with sorafenib plus or minus
IPI145; p values were calculated comparing each treatment group to untreated (UT).
(E) CD8+ CTLs from tumors of mice treated with sorafenib plus IPI145.
(F)Perforin expression in CD8+CTLs from tumors ofmice treatedwith sorafenib plus IPI145. Dotted lines indicate baseline gene expression in untreated samples.
*p% 0.05 versus untreated; #p% 0.05 versus 4 week sorafenib alone. Data from untreated and sorafenib-treated tumors from Figures 2B–2E and 4B–4G are
presented in (A)–(F) for comparison. Mean ± SEM is presented for all quantitation.
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increase the sensitivity of PyMT tumors to DC101. Of note, simi-
larly to the PNET cells, PyMT breast tumor cells did not express
detectable levels of PI3Kg or PI3Kd, and did not respond to
IPI145 in vitro (Figures S7D and S7E). Indeed, we found that
combining IPI145 with DC101 substantially reduced the number
of tumor-associated pS6+ CD11b+ cells to 9% (Figure 7D). This
corresponded to a reduction in tumor growth, with a further trend
in microvessel density reduction concomitant with enhanced
immune-stimulatory and reduced immune-suppressive gene
expression profiles (Figures 7E, 7F, 7H, and 7I). IPI145 decreased
the levels of intratumoral TAM, Gr1+ monocytes, and TAN
compared with both control and DC101-treated tumors (Figures
7G and S7C), and further enhancedCXCL4 andCXCL14 expres-
sion, similar to the results observed in the PNETmodel (Figure 7I).
As expected, IPI145 repressed DC101-induced expression of IL-
10 and TGFb1, and induced IL-23 and TNFa expression in TAM,
Gr1+ monocytes, and TAN (Figures S6A–S6D). Furthermore, it
enhanced CXCL4 and CXCL14 expression in these populations
and repressed DC101-induced VEGF and bFGF transcription
(Figures S6A–S6D). Consequently, IPI145 induced Perforin
expression in tumor-associated CTLs (Figures S6E and S6F).
Thus, in the PyMT and PNET models, PI3K activation in myeloid
cells hindered the efficacy of antiangiogenic therapy by promot-
ing immune suppression and limiting the expression of angio-
static factors. These results not only demonstrate that oscillating
immune cells activate PI3K signaling to mediate resistance, but
also suggest that the extent of PI3K-activated myeloid cells
may predict tumor response to antiangiogenic therapy.
DISCUSSION
In this study, we demonstrated that intratumoral myeloid cells
dynamically drive responsiveness as well as resistance to angio-
genic inhibitors targeting the VEGF/VEGFR pathway. Sorafenib
and DC101 skewed different inert CD11b+ myeloid cell popula-
tions, including TAM, TAN, and Gr1+Ly6CHi and Ly6GHi mono-
cytes, to an immune-stimulatory and angiostatic phenotype in
tumors by enhancing their expression of the angiostatic and im-
mune-stimulatory chemokine CXCL14 (and to a lesser extent
CXCL4). Surprisingly, the efficacy of the VEGF/VEGFR inhibitors
depended on the induction of these myeloid CXCL chemokines
rather than on direct inhibition of VEGFR signaling in endothelial
cells. Although depleting CTL cells during antiangiogenic ther-
apy in RT2 mice lowered the apoptotic rate without affecting
vessel density, blocking CXCL14 was sufficient to disable
both the reduction in vessel density and enhanced tumor cell
apoptosis, thereby completely abrogating the ability of sorafenib
to promote tumor stasis. While CXCL4 is believed to induce anti-
angiogenic activity by interfering with integrins on the surface of
endothelial cells (Aidoudi et al., 2008;Maione et al., 1990; Sharpe
et al., 1990), less is known about the mechanism underlying the
antiangiogenic activity of CXCL14, although CXCL14 is known
for its effects on dendritic cell maturation (Shellenberger et al.,
2004). Other CXCL chemokines, such as CXCL9 and CXCL10,
have also been identified in macrophages that exert angiostatic
functions, implying a myeloid-specific angiostatic signature
(Mantovani et al., 2005). Our findings reveal the necessity of us-
ing myeloid cells in antiangiogenic therapy, and show that theproangiogenic capacity observed in immunosuppressive
myeloid populations does not stem from the enhanced expres-
sion of angiogenic factors, but rather from the repression of an-
giostatic CXCL chemokines that also elicit immune-stimulating
functions.
In order to reinitiate angiogenesis and immune suppression,
tumors induced infiltration of Gr1+ monocytes and neutrophils,
and produced factors that activated the PI3K signaling axis in
all CD11b+ immune cells. This rendered myeloid cells nonre-
sponsive to angiogenesis inhibitors and increased their proan-
giogenic and immune-suppressive properties (Figures 7J and
7K). Our findings further reveal that the PI3K-activation status
of myeloid cells in tumors determines the efficacy of antiangio-
genic therapy. In naive PNETs, most myeloid cells were inactive,
leading to a pronounced antiangiogenic effect; however, in
PyMT tumors, with more than 40% myeloid PI3K activity, ther-
apy only partially impaired angiogenesis and tumor growth.
Interestingly, targeting the enhanced influx of Gr1+ cells was
not sufficient to prolong the response to angiogenic blockade in
both tumor models, as it resulted in an increase in TAM concom-
itant with enhanced intratumoral M-CSF levels. Targeting TAM
induced an increase in Gr1+ cells due to elevated G-CSF levels
(Figures S2D–S2F), leading to an oscillating pattern of distinct im-
mune cell populations. Chemotherapeutics are commonly given
in conjunction with antiangiogenic agents and have been shown
to modulate immune suppression (Coussens et al., 2013). How-
ever, addition of the chemotherapeutic temolozolomide (TMZ)
did not affect either the oscillating compensation of myeloid cells
when TAM or Gr1+ cells were targeted during antiangiogenic
therapy or the timing of the angiogenic relapse, although it further
reduced tumor burden by about 30% (Figures S2G–S2I). Further
evidence for oscillating resistance comes from a previous study
in which genetic depletion of TAMs (the major source of the
proangiogenic enzyme MMP9) in a transgenic mouse model of
cervical cancer resulted in a compensatory increase in TAN,
which then became the primary source of MMP9, promoting
neovascularization (Pahler et al., 2008). Furthermore, various
approaches to deplete TAM in models of thyroid, cervical, and
pancreatic cancers have also been shown to increase tumor-
associated Gr1+ cells (Mitchem et al., 2013; Ryder et al., 2013).
Interestingly, however, Gr1+ cells in the absence of TAM could
not compensate for the TAM-dependent maintenance of the
ALDH+ cancer stem cell fraction in PDAC (Mitchem et al., 2013)
or the growth deficiency of Braf-driven thyroid tumors (Ryder
et al., 2013). Taken together, these results support the notion
that innate immune cells share functions in angiogenesis and
immune modulation, likely to maintain tissue homeostasis, but
also have distinct and noncompensatory functions in other areas
such as stemcellness, invasion, and metastasis (Mitchem et al.,
2013; Qian and Pollard, 2010; Yang et al., 2008).
Furthering the concept of functional redundancies among tu-
mor-infiltrating myeloid cells in angiogenesis and immune sup-
pression, we identified two Th2-skewed myeloid phenotypes
(simplistically referred to as ‘‘M2’’-like) that differed in their
PI3K-activation status (Figures 7J and 7K). Whereas PI3K-inert
myeloid cells expressed several proangiogenic factors and
lacked immune-stimulating activity (M2 cells), myeloid cells with
active PI3K signaling aggravated angiogenic and immune-Cell Reports 11, 577–591, April 28, 2015 ª2015 The Authors 587
(legend on next page)
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suppressive activities, and thwarted the immune-stimulatory and
angiostatic conversion by VEGF/VEGFR inhibitors (M2* cells).
Interestingly, M2* cells exhibited an expression profile, including
increased MMR (MRC1) levels, that was in part reminiscent of a
Tie2-expressing monocyte (TEM) signature (Pucci et al., 2009;
Squadrito et al., 2012). TEMs are a subpopulation of TAMs that
exhibit exacerbated angiogenic activity and were also found to
accumulate in relapsing tumors undergoing anti-VEGFR therapy
(Rigamonti et al., 2014). Therefore, it is intriguing to speculate
that the TEM signature is in part regulated by macrophage PI3K
activation.
In contrast to epithelial cells and cancer cells, myeloid cells
specifically express the g and d isoforms of PI3K, which can
be blocked with IPI145. Although we did not differentiate be-
tween PI3Kg and PI3Kd activity, PI3Kg is highly enriched in
myeloid cells, where it transduces GPCR, TLR, and RTK
signaling to facilitate myeloid cell infiltration to inflammatory
sites and evoke inflammatory responses in tumors and other
diseases (Gonza´lez-Garcı´a et al., 2010; Hirsch et al., 2000;
Schmid et al., 2011), suggesting that the g isoform is the major
regulator of tumor inflammation in myeloid cells. Several tumor-
derived chemoattractants have been described to activate
PI3Kg signaling (Schmid et al., 2011; Hirsch et al., 2000). Among
these, we found IL-6 and SDF1a to be upregulated in relapsing
PNETs. As SDF1a and IL-6 are hypoxia-regulated genes, it is
conceivable that microenvironmental changes, such as ther-
apy-induced hypoxia, promote such a conversion. Indeed,
macrophage polarization is regulated in part by intratumoral
hypoxia, in which Semaphorin 3A/Neuropilin-1 signaling en-
ables the infiltration of myeloid cells into hypoxic areas in which
they secrete various immune-suppressive and proangiogenic
factors (Casazza et al., 2013; De Palma and Lewis, 2013; Qian
and Pollard, 2010).
Together, these data provide a rational basis for future thera-
peutic modalities to combine antiangiogenic and immune
therapies to generate more durable effects and likely sensitize
resistant tumors to antiangiogenic therapy. This is furtherFigure 7. Myeloid PI3K Limits Antiangiogenic Therapy in PyMT Tumor
(A) PyMT tumor growth. *p < 0.05 for treatment groups versus control at day 12.
(B) Microvessel density of tumors at day 12 of treatment.*p < 0.05 versus contro
(C) Intratumoral myeloid cell composition at day 12 of treatment. p < 0.05 for TAM
Gr1; p < 0.05 for TAM and TAN from DC101 versus DC101 plus anti-CSF1 at 12
(D) CD11b+ pS6 staining and quantification of PyMT tumors. Scale bars, 5 mm.
(E) Tumor growth in mice treated with IPI145 as indicated. *p < 0.05 for DC101, IP
day 12. Data represent at least six mice per group.
(F and G) Microvessel density (F) and myeloid cell composition (G) in tumors after
TAN in DC101 plus IPI145 versus cognate populations in DC101 alone.
(H and I) qPCR analyses of immune- (H) and angiogenesis- (I) modulating genes (H
12-day control. Dotted lines indicate baseline gene expression in control sample
(J and K) Summary of responses to antiangiogenic therapy in RT2 (J) and PyMT
(J) Myeloid cells in naive RT2 PNET exhibit a ‘‘PI3K-off’’ M2 phenotype. Angiogene
which promotes tumor response by impeding angiogenesis and facilitating an
increasing SDF1a and IL-6. PI3K-activated myeloid cells display a highly angi
resistance to therapy by blocking antitumor immunity and promoting angiogenesis
response.
(K) Myeloid cells within PyMT tumors are both M2 and M2*. Antiangiogenic thera
while IPI145 alone converts M2* cells to an M1 phenotype and does not influe
combining angiogenesis inhibitors and IPI145 results in conversion of both M2 a
See Discussion for details and also Figures S6 and S7.supported by observations that the abnormal tumor vasculature
fosters an immune-suppressive microenvironment that enables
tumors to evade host immunosurveillance (Motz and Coukos,
2013). In addition, the proangiogenic factor VEGF not
only suppresses the function of various immune cells but also di-
minishes leukocyte-endothelial interactions, thereby hindering
infiltration of immune T-effector cells into the tumor (Bouzin
et al., 2007; Gabrilovich et al., 1996; Griffioen et al., 1996; Motz
and Coukos, 2011). Congruently, VEGF blockade was recently
found to result in TAM polarization toward an immune-support-
ing state and increased T cell infiltration into tumors by creating
an even distribution of patent vessels that reduced tumor hypox-
ia (Huang et al., 2012), whereas genetic deletion of Rgs5 in
pericytes increased T cell infiltration into tumors and enhanced
survival after adoptive T cell transfer by normalizing the tumor
vasculature (Hamzah et al., 2008).
The existence of oscillating innate immune cells to convey re-
neovascularization supports the idea of modulating the overall
immune response to control tumor growth, as opposed to tar-
geting distinct myeloid populations, because this approach
would not leave behind nontargeted myeloid cells able to foster
tumor reneovascularization. We found that PI3K inhibition in
all myeloid cells generated an enduring angiostatic and im-
mune-stimulatory environment in which antiangiogenic therapy
remained efficient. Other approaches to reverse immune sup-
pression, including blockade of self-tolerance checkpoints, are
showing increasing promise, with the anti-CTLA-4 antibody ipi-
limumab having already received FDA approval for advanced
melanoma. Various antiangiogenic immune therapies have
been tested in the clinic, more recently in combination with
checkpoint blockers, with encouraging results (Garber, 2014;
Schoenfeld and Dranoff, 2011). Ongoing and future studies
will reveal whether combining antiangiogenic therapies with
these new immune-modulating strategies will more robustly
inhibit tumor angiogenesis and promote an enduring immune-
stimulatory milieu that could lead to prolonged survival in cancer
patients.s
Data represent at least six mice per group.
l.
, Gr1+Ly6GHi monocytes, and TAN from DC101 alone versus DC101 plus anti-
days.
I145 versus control at day 12; #p < 0.05 for DC101 plus IPI145 versus DC101 at
12 days of treatment. *p < 0.05 versus control at 12 days. p < 0.05 for TAM and
) after 4 and 12 days of therapy. *p < 0.05 versus 4-day control; #p < 0.05 versus
s. Mean ± SEM is presented for all quantitations.
(K) models.
sis inhibitors skewmyeloid cells toward a CXCL14-expressing M1 phenotype,
titumor immunity. In turn, tumors activate myeloid PI3K signaling, likely by
ogenic and immune-suppressive M2* phenotype. M2* myeloid cells convey
. IPI145 blocks acquisition of theM2* phenotype, resulting in a sustained tumor
py alone skews M2 cells toward an M1 phenotype without affecting M2* cells,
nce M2 cells. Thus, either treatment elicits only partial responses, whereas
nd M2* cells to the M1 phenotype, thereby enhancing the tumor response.
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EXPERIMENTAL PROCEDURES
For more details regarding the materials and methods used in this work, see
the Supplemental Experimental Procedures.
Tumor Models
RT2 mice (previously described in Hanahan, 1985) were maintained as hetero-
zygotes in the C57BL/6 background. Sorafenib treatment with or without TMZ
was initiated at 13 weeks of age and administered until the mice reached the
age of 15 weeks or 17 weeks. Mice were treated with anti-Gr1, anti-CSF1, or
IPI145 (Active Biochem) beginning at 15 weeks, 2 weeks after initiating sorafe-
nib treatment. For PyMT experiments, syngeneic PyMT breast tumor cells
were implanted into the fourth mammary fat pads of female FVB mice at
4–5 weeks of age. Tumors reached 5 mm in diameter before DC101 treatment
was initiated alone or in combination with anti-Gr1 or anti-CSF1. All animal
studies were reviewed and approved by the UCSF Institutional Animal Care
and Use Committee. For more experimental details, see the Supplemental
Experimental Procedures.
Human PNET Specimens
Immune cells were assessed for pS6 staining by a neuropathologist (D.M.) in
34 deidentified tumor samples from Hospices Civils de Lyon, representing
naive-treated patients and patients treated with 5-FU or bevacizumab.
To confirm this assessment, immunofluorescent staining for CD45 and
pS6 was performed blindly on tumor samples corresponding to eight un-
treated patients, six patients treated with 5-FU, and two patients treated
with bevacizumab.
Expression Analysis
qPCR expression analyses were performed using whole-tumor or FACS-
sorted cell populations and the indicated primer sets. Relative gene expres-
sion was calculated as previously described (Livak and Schmittgen, 2001).
In brief, L19 was used as a housekeeping gene to generate DCt. DCt values
from untreated mice were used as reference for treatment groups to generate
DDCt, and relative gene expression was calculated as 2(DDCt). Analyses of
sorted cells from RT2 mice were performed using at least eight experimental
mouse replicates, andwhole-tumor analyseswere performed using five exper-
imental replicates. Analyses of sorted cells from PyMT tumors as well as whole
PyMT tumors were performed using at least six experimental mouse repli-
cates. All reactions were run in triplicate. For primer sequences, see the Sup-
plemental Experimental Procedures.
Statistical Analyses
Statistical analyses were performed under the guidance of the Helen Diller
Family Comprehensive Cancer Center Biostatistics and Computational
Biology Core. For mouse studies, p values for RT2-PNET and PyMT tumor
burdens were calculated using the Wilcoxon rank sum test. The p values for
microvessel density, multicolor flow cytometry, CD11b/pS6 and CD45/pS6
immunostaining, and CD8+ T cell content were also calculated using the Wil-
coxon rank sum test. This same test was used to evaluate survival (since un-
censored). For gene expression analyses, where the transformed signals were
more Gaussian and the sample sizes were smaller, comparisons between
experimental and control mice for single genes weremade using a two-sample
t test. To determine whether a signature (e.g., immune response or angiogen-
esis) was present, p values were added across genes. For this purpose,
Fisher’s inverse chi-square method was utilized.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.03.055.
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